Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of June 2023. The report, dated June 26, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The provided filing text does not contain specific financial data. It serves as a cover document incorporating a press release by reference. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.
Material Changes
The filing text does not disclose specific material changes versus prior periods. The content is limited to the incorporation of a press release, the details of which are not included in the provided input.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. The document indicates that the substantive information is contained within the referenced press release (Exhibit 99.1), which is not included in the source text.
Investor Verification Checklist
- Verify the content of the press release dated June 26, 2023 (Exhibit 99.1), as the filing relies on it for substantive details.
- Confirm the specific clinical or corporate developments announced in the referenced press release.
- Review the company's Form 20-F for the most recent audited financial statements, as this 6-K does not contain financial tables.